Gilead Adefovir Approval Awaits "Unequivocal" Evidence Of Efficacy At 60 mg

Gilead has begun enrollment in two placebo-controlled trials of a 60 mg dose of adefovir dipivoxil that could provide sufficient evidence to prompt a reconsideration of the HIV therapy by FDA's Antiviral Drugs Advisory Committee.